This application requests renewal for years 29-33 of the NCI Cancer Center Support Grant (CCSG) for the Barbara Ann Karmanos Cancer Institute (KCI) at Wayne State University. The Programs of KCI reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. KCI has a long-standing and extensive commitment to both research and clinical services that address the prevention, early detection and treatment of cancer, particularly of African Americans who carry a disproportionate cancer burden. This application requests support for five Programs, ten Cores, Developmental Funds, five Staff Investigators, and related administrative support. KCI's established Programs are Breast Cancer Biology;Developmental Therapeutics;Molecular Biology and Genetics;Population Studies and Disparities Research, and Proteases and Cancer. Our Programs are organized to integrate basic, translational, and clinical research with population research-based cancer control activities. Additionally, CCSG support is requested for ten Cores, in Behavioral and Field Research;Biorepository;Epidemiology Research;Genomics;Microscopy, Imaging and Cytometry Resources;Pharmacology;Proteomics;Systems and Computational Biology;Biostatistics;and Clinical Trials Office. KCI fosters inter-disciplinary interactions and collaborations, utilizes CCSG Developmental Funds to recruit new investigators, encourages translational research Programs, and develops new Shared Resources (Cores) to support KCI members. Research growth continues, as demonstrated by increases in the number of publications and the recruitment of internationally recognized scientists. KCI has 235 members, 170 are Scientific Members and 65 are Clinical Members representing 40 departments and institutes from Wayne State University, Henry Ford Health System, University of Windsor, and Michigan State University. KCI's total annual direct grant funding is $63,296,703 of which $42,441,739 is peer reviewed funding. Of the peer reviewed funding, 6 1 % is from NCI. Over the last grant period, members'published 2,980 papers, 38% and 35% were intra- and inter-programmatic, respectively and 24% were both intra- and inter-programmatic.

Public Health Relevance

Cancer is the second leading cause of mortality in the United States and disproportionately affects minorities. It is through the clinical, basic, population and translational research conducted at KCI that we can make strides towards reducing mortality and morbidity associated with cancer, with a continued commitment to address the disproportionate cancer burden among minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600843
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-08
Project End
2015-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$2,281,870
Indirect Cost
$780,640
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164
Eggly, Susan; Hamel, Lauren M; Foster, Tanina S et al. (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns 100:818-826
Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga et al. (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7:44125
Bernardo, Margarida M; Dzinic, Sijana H; Matta, Maria J et al. (2017) The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. J Cell Biochem 118:1639-1647
Soave, Claire L; Guerin, Tracey; Liu, Jinbao et al. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev 36:717-736
Jones, Carissa C; Bush, William S; Crawford, Dana C et al. (2017) Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiol Biomarkers Prev 26:1288-1295
Bosnyák, Edit; Michelhaugh, Sharon K; Klinger, Neil V et al. (2017) Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 42:341-347
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Tan, Zhijing; Nie, Song; McDermott, Sean P et al. (2017) Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res 16:842-851
Embogama, D Maheeka; Pflum, Mary Kay H (2017) K-BILDS: A Kinase Substrate Discovery Tool. Chembiochem 18:136-141

Showing the most recent 10 out of 726 publications